RecruitingNCT06029933

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Relative Vaccine Effectiveness of Adjuvanted Quadrivalent Inactivated Influenza Vaccine vs High-Dose Quadrivalent Inactivated Influenza Vaccine Among Adults ≥65 Years for the 2023-24 and 2024-25 Seasons


Sponsor

Kaiser Permanente

Enrollment

960,000 participants

Start Date

Aug 17, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24 and 2024/25 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.


Eligibility

Min Age: 65 Years

Inclusion Criteria3

  • Age ≥65 years at the time of influenza vaccination
  • KPNC member at the time of vaccination
  • Receive either aIIV4 or HD-IIV4 at a KPNC facility during the 2023/24 and/or 2024/25 influenza seasons

Exclusion Criteria4

  • Age \<65 years at the time of influenza vaccination
  • Received either aIIV4 or HD-IIV4 in the inpatient setting
  • Receive more than one influenza vaccination during a single season period (i.e., 2023/24 or 2024/25 influenza seasons)
  • Receive an influenza vaccination outside of KPNC

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAdjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)

Fluad Quadrivalent vaccine is an inactivated influenza vaccine formulated to contain 60 mcg of hemagglutinin (HA) total, with 15 mcg from each of the four recommended influenza strains and the MF59 adjuvant in single-dose prefilled 0.5 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluad as part of routine clinical care during the influenza season.

BIOLOGICALHigh-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)

Fluzone High-Dose Quadrivalent vaccine is an inactivated split virion influenza vaccine formulated to contain 240 mcg of HA total, with 60 mcg from each of the four recommended influenza strains in single-dose prefilled 0.7 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluzone High-Dose as part of routine clinical care during the influenza season.


Locations(1)

Kaiser Permanente Northern California (entire region)

Oakland, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06029933


Related Trials